Skip to main content
. 2015 Feb 12;6(2):e1637. doi: 10.1038/cddis.2015.2

Figure 4.

Figure 4

Figure 4

PAK1 kinase activity inhibition enhances sunitinib sensitivity in RCC cells. (a) Western blot analysis of PAK1, p-PAK1(T423) and GAPDH for ACHN cells stably transfected with NS-shRNA and PAK1-shRNA-1 without or with sunitinib (5 μM) treatment for 48 h (left panel), for ACHN cells stably transfected with control (empty vector) or PAK1-K299R without or with sunitinib (5 μM) treatment for 48 h (middle panel), for OS-RC-2 cells in the presence with IPA3 (7.5 μM) with or without sunitinib (5 μM) treatment for 48 h (right panel). GAPDH was used as a loading control. The numbers shown are the ratios of the intensities of the bands for p-PAK1(T423) divided by the intensities of the bands for GAPDH, normalized to 1.00 for ACHN cells transfected with NS-shRNA, and OS-RC-2 cells without treatment with sunitinib, respectively. (b) Analysis of self-renewal of ACHN and OS-RC-2 cells with above-mentioned treatment. Data are represented as means±S.D. of triplicate experiments. *P<0.05 versus sunitinib. (c) Flow cytometry analysis of ALDH1, CD73 and CD146 for ACHN and OS-RC-2 cells with above-mentioned treatment from generations G3 spheres. Data are represented as means±S.D. of triplicate experiments. *P<0.05 versus sunitinib. (d–f) Cell proliferation assay (d), annexin V/PI staining assay (e) and caspase 3/7 activity (f) for ACHN and OS-RC-2 cells with above-mentioned treatment. Data are represented as means±S.D. of triplicate experiments. *P<0.05